Dissemin is shutting down on January 1st, 2025

Published in

Impact Journals, Oncotarget, 42(7), p. 69060-69074, 2016

DOI: 10.18632/oncotarget.11264

Links

Tools

Export citation

Search in Google Scholar

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

Journal article published in 2016 by Valentina Fanotto, Elena Ongaro, Karim Rihawi, Antonio Avallone ORCID, Nicola Silvestris, Lorenzo Fornaro, Enrico Vasile, Lorenzo Antonuzzo ORCID, Francesco Leone, Gerardo Rosati, Francesco Giuliani, Roberto Bordonaro, Mario Scartozzi, Giovanna De Maglio, Giovanna De Maglio and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.